William Blair analyst Lachlan Hanbury-Brown reiterated an Outperform rating on ARS Pharmaceuticals Inc (NASDAQ: SPRY)The analyst commented, "We view this ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE